Nektar Therapeutics (NKTR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Puma Biotechnology, Inc.

Protalix Biotherapeutics, Inc.

Gamida Cell Ltd.

Nektar Therapeutics

Mind Medicine (MindMed), Inc.

Talaris Therapeutics, Inc.

Annexon, Inc.

Adverum Biotechnologies, Inc.

ESSA Pharma, Inc.

Calidi Biotherapeutics, Inc.

Ocean Biomedical, Inc.

Why is Nektar Therapeutics ?

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of -14.34% and Operating profit at 10.24% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -7.59

The company has declared negative results in Mar'2025 after 2 consecutive positive quarters

NET SALES(Q) At USD 11.18 MM has Fallen at -48.77%
ROCE(HY) Lowest at -440.8%
PRE-TAX PROFIT(Q) At USD -38.95 MM has Fallen at -36.82%

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 269.11%, its profits have risen by 18%

Reducing Promoter Confidence

Promoters have decreased their stake in the company by -0.56% over the previous quarter and currently hold 2.17% of the company
Promoters decreasing their stake may signify reduced confidence in the future of the business

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Nektar Therapeutics for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Nektar Therapeutics

259.44%

0.19

1239.96%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-14.34%

EBIT Growth (5y)

10.24%

EBIT to Interest (avg)

-7.59

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-8.04

Sales to Capital Employed (avg)

0.47

Tax Ratio

0.12%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

9.02

EV to EBIT

-0.10

EV to EBITDA

-0.10

EV to Capital Employed

-0.14

EV to Sales

0.15

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-860.22%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

4What is working for the Company

NET PROFIT(HY)

Higher at USD -91.86 MM

RAW MATERIAL COST(Y)

Fallen by -68.76% (YoY

-18What is not working for the Company

NET SALES(Q)

At USD 11.18 MM has Fallen at -48.77%

ROCE(HY)

Lowest at -440.8%

PRE-TAX PROFIT(Q)

At USD -38.95 MM has Fallen at -36.82%

NET PROFIT(Q)

At USD -41.15 MM has Fallen at -39.27%

CASH AND EQV(HY)

Lowest at USD 394.53 MM

DEBT-EQUITY RATIO (HY)

Highest at -3.41 %

Here's what is working for Nektar Therapeutics

Raw Material Cost

Fallen by -68.76% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Nektar Therapeutics

Net Sales

At USD 11.18 MM has Fallen at -48.77%

over average net sales of the previous four periods of USD 21.81 MM

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit

At USD -38.95 MM has Fallen at -36.82%

over average net sales of the previous four periods of USD -28.47 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -41.15 MM has Fallen at -39.27%

over average net sales of the previous four periods of USD -29.54 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Cash and Eqv

Lowest at USD 394.53 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -3.41 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio